Clinical Study
Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate
Table 1
Comparison of patients’ characteristics and serum MTX concentrations between patients with and without MTX elimination delay.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S-creatinine 0 h: serum creatinine level before MTX infusion; S-creatinine 24 h: serum creatinine level in 24 hours after MTX infusion; S-creatinine 48 h: serum creatinine level in 48 hours after MTX infusion; S-creatinine ratio 24 h: the ratio of serum creatinine level in 24 hours to creatinine level before MTX infusion; S-creatinine ratio 48 h: the ratio of serum creatinine level in 48 hours to creatinine level before MTX infusion; CCR_0 h: creatinine clearance rate before MTX infusion; CCR_24 h: creatinine clearance rate in 24 hours after MTX infusion; CCR_48 h: creatinine clearance rate in 48 hours after MTX infusion; CCR_96 h: creatinine clearance rate in 96 hours after MTX infusion; _24 h: serum MTX concentration in 24 hours after MTX infusion; _48 h: serum MTX concentration in 48 hours after MTX infusion; _96 h: serum MTX concentration in 96 hours after MTX infusion. |